These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 23026665)

  • 21. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
    Bauer KA
    Stroke; 2013 Jun; 44(6 Suppl 1):S38-40. PubMed ID: 23709725
    [No Abstract]   [Full Text] [Related]  

  • 22. [New anticoagulants: better knowledge, better prescriptions].
    Boehlen F; de Moerloose P
    Rev Med Suisse; 2012 Jan; 8(324):96-9. PubMed ID: 23185817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current and future therapies for prophylaxis of thromboembolism in atrial fibrillation].
    Geisler T; Gawaz M
    MMW Fortschr Med; 2011 Apr; 153(15):27-30; quiz 31. PubMed ID: 21667556
    [No Abstract]   [Full Text] [Related]  

  • 24. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
    Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
    Kasmeridis C; Lip GY; Apostolakis S
    Hosp Pract (1995); 2013 Feb; 41(1):61-70. PubMed ID: 23466968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
    Tendera M; Syzdół M; Parma Z
    Cardiol J; 2012; 19(1):4-10. PubMed ID: 22298161
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apixaban for the prevention of stroke in atrial fibrillation.
    Littrell R; Flaker G
    Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):143-9. PubMed ID: 22292869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
    Lenchus JD
    Hosp Pract (1995); 2013 Feb; 41(1):49-60. PubMed ID: 23466967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Atrial fibrillation: what the GP needs to know].
    Diener HC; Kaeufer T; Bode C
    MMW Fortschr Med; 2011 Sep; 153(38):44-7; quiz 48. PubMed ID: 21977796
    [No Abstract]   [Full Text] [Related]  

  • 30. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
    ROCKET AF Study Investigators
    Am Heart J; 2010 Mar; 159(3):340-347.e1. PubMed ID: 20211293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new era of antithrombotic therapy in patients with atrial fibrillation.
    Golwala H; Dib C; Tafur A; Abu-Fadel MS
    Am J Med Sci; 2012 Aug; 344(2):128-35. PubMed ID: 22245946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New anticoagulants for atrial fibrillation.
    De Caterina R; Kristensen SD; Renda G
    J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):446-53. PubMed ID: 19365276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Improvements in oral anticoagulant therapy for atrial fibrillation].
    Briongos Figuero S; García Santos-Gallego C; Badimón JJ
    Med Clin (Barc); 2013 Dec; 141(11):487-93. PubMed ID: 23597953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
    Tripodi A; Palareti G
    J Intern Med; 2012 Jun; 271(6):554-65. PubMed ID: 22443239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Novel oral anticoagulants and atrial fibrillation in the elderly].
    Hanon O
    Geriatr Psychol Neuropsychiatr Vieil; 2013 Dec; 11(1 Suppl):34-40. PubMed ID: 24463062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
    Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
    J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
    Albert NM
    Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New oral anticoagulants in elderly patients.
    Barco S; Cheung YW; Eikelboom JW; Coppens M
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):215-24. PubMed ID: 23953909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. {blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
    Drug Ther Bull; 2014 Jan; 52(1):6-9. PubMed ID: 24401533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.